Intranasal medicinal composition containing bilastine and mometasone furoate
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- 于运红
- Publication Date
- 2014-04-23
- Estimated Expiration
- Not applicable · inactive patent
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
field of invention
[0001] The present invention relates to a pharmaceutical composition for intranasal administration containing mometasone furoate and bilastine, in particular to a pharmaceutical composition for intranasal administration, which uses thaumatin to relieve bilastine The bitterness and irritation of the nose improves the nasal dripping feeling. Background of the invention
[0002] Mometasone furoate, as a steroid drug for the treatment of allergic rhinitis, is known to have an excellent effect of continuously relieving symptoms, and bilastine, as a short-acting antihistamine, is known to have an excellent ability to immediately improve symptoms. Therefore, when these two drugs are administered as a combined preparation, it is expected to exhibit an excellent effect in the long-term treatment of allergic rhinitis while improving symptoms immediately.
[0003] Bilastine is a highly selective histamine H1 receptor antagonist without sedative effect, which is used...